Abstract
Ischemic diseases are major contributors to global morbidity and mortality, posing a substantial threat to human health. Extracellular vesicles (EVs) play an essential role in enhancing neovascularization in ischemic tissues, thereby facilitating tissue repair and regeneration. However, the utilization of EVs is hindered by their rapid uptake and clearance by the mononuclear phagocyte system (MPS), which markedly impedes their therapeutic efficacy and organ-specific accumulation. Notably, CD47, upon binding to signal regulatory protein alpha, initiates a "don't eat me" signal, enabling immune evasion from the MPS. Our research has demonstrated that phagocytes predominantly engulf CD47<sup>low</sup> dendritic DC2.4 cell-derived EVs (DV), while engineered CD47<sup>high</sup> EVs (MV<sup>47</sup>) experience minimal ingestion. Leveraging these findings, we have developed a dual-faceted "Engage & Evasion" strategy. Initially, DVs were employed to saturate the MPS, serving as the "engage" component. Subsequently, MV<sup>47</sup>, fortified with CD47, was introduced for "evasion" purposes. This approach effectively minimized entrapment by the liver and spleen, boosted serum concentration, and enhanced final accumulation in non-MPS organs. In summary, our "Engage & Evasion" therapeutic strategy offers a promising avenue to enhance EV therapeutic potential against ischemic challenges through improved systemic distribution.
Introduction: The Challenge of EV Delivery
Extracellular vesicles (EVs) are natural, membrane-bound "delivery trucks" that carry bioactive proteins and RNA capable of triggering tissue repair. While they hold immense promise for regenerative medicine, particularly in treating ischemic diseases like myocardial infarction and hindlimb ischemia, they face a significant "last-mile" delivery problem.
Upon systemic administration, the Mononuclear Phagocyte System (MPS)—primarily macrophages located in the liver and spleen—recognizes EVs as foreign and rapidly clears them from circulation. This rapid sequestration prevents a therapeutic dose from reaching the target damaged tissues. While engineering EVs with CD47 (a "don't eat me" signal) has been explored, it is often insufficient on its own to overcome the massive clearing capacity of the MPS.
The "Engage & Evasion" Strategy
To address this limitation, this study introduces a sequential "Engage & Evasion" administration protocol designed to "blindside" the immune system.
- The "Engage" Phase: The first step involves injecting decoy EVs derived from DC2.4 dendritic cells (DVs). These vesicles possess a high natural affinity for macrophages. By administering them first, the researchers "engage" the MPS, effectively saturating the phagocytic capacity of the liver and spleen.
- The "Evasion" Phase: Approximately four hours later, therapeutic EVs derived from Mesenchymal Stem Cells (MSCs) are injected. These vesicles (MV<sup>47</sup>) are genetically engineered to overexpress CD47, which binds to the SIRPα receptor on macrophages to actively inhibit their uptake.
This dual approach ensures that the "hungry" macrophages are occupied by the decoy DVs, allowing the stealth-engineered MV<sup>47</sup> to bypass the MPS and reach the ischemic target sites.
Experimental Validation and Key Results
The study utilized advanced imaging and molecular techniques to validate this strategy. Single-vesicle interferometric imaging (ExoView 200) confirmed the expression of key surface markers (CD81, CD9, CD47) on the engineered vesicles.
Molecular Insights into MPS Saturation
RNA-sequencing of Kupffer cells (liver macrophages) revealed that the "Engage" step is more than just a physical blockade. The decoy vesicles trigger a molecular shift, downregulating genes involved in phagocytosis and myeloid activation (e.g., Ugt1a1 and Exosc6), temporarily reducing the immune system's overall "appetite."
Enhanced Biodistribution and Therapeutic Efficacy
In vivo testing in mouse models of Myocardial Infarction (MI) and Hindlimb Ischemia (HLI) demonstrated the superiority of the combined strategy:
- Biodistribution: IVIS imaging showed significantly reduced accumulation of therapeutic EVs in the liver and spleen, with a corresponding increase in serum concentration and target tissue accumulation.
- Cardiac Recovery: In the MI model, the "Engage & Evasion" group exhibited significant improvements in Left Ventricular Ejection Fraction (EF) and Fractional Shortening (FS) by Day 28, alongside a reduction in infarct size.
- Limb Perfusion: Laser Doppler measurements in the HLI model showed significantly higher blood flow recovery in dual-treated mice compared to controls.
- Neovascularization: The therapeutic EVs were shown to directly enhance the migration and tube-forming ability of endothelial cells, promoting the growth of new blood vessels.
Conclusion and Future Directions
The "Engage & Evasion" strategy represents a significant advancement in nanomedicine, providing a robust method to overcome the MPS barrier. By combining immune system distraction with stealth engineering, the researchers achieved superior therapeutic outcomes in ischemic disease models without hepatorenal toxicity.
Future work will focus on optimizing the therapeutic "cargo" (such as specific miRNAs or drugs) within these stealth vesicles and scaling up production for potential clinical translation.
Data Availability: Genome-wide RNA-sequencing data from DV-primed hepatic CD11b+ Kupffer cells is available in the Genome Sequence Archive (accession: CRA016382).
Summary updated